iGenomes data set....which to use?
Can anyone shed any light on the relative merits of the 3 sources of reference data available on iGenomes (UCSC/NCBI/Ensembl)?
Thanks
Huw
Thanks
Huw
-
-
They all (currently) share the same genome assembly for humans and mice.
The differ in the annotation (where exactly are genes, what are they called, how do the transcripts look like?).
I personally prefer to work with Ensembl, since they have a clear release policy (making it easy to reference the exact data you were using) , archives of older releases , a consistent set of 'stable ids' for genes/transcripts/proteins, the largest set of (chordata) genomes and provide backlinks for the evidence for each transcript.
UCSC is often a bit more cutting edge, they have somewhat of an ongoing release process, nowadays include ENCODE genes (which in turn come from Ensembl...).
Can't really say anything about the NCBI.
So long,
Florian -
Good question. I've heard anecdotally that using cufflinks with RABT assembly using refseq/ucsc gives you MANY more novel isoforms than when using Ensembl. Why or whether that's a bad thing, I'm not sure.Comment
-
@turnersed: Guess the first question is whether they're real 'novel' isoforms, or had already been in Ensembl.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment